Ginkgo Bioworks Holdings has seen its consensus analyst price target rise from $11.33 per share to $12.00 per share. This reflects a modest but noteworthy vote of confidence from the market. The ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $15.24, moving -5.28% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.28%.

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API ...

Enzyme Intelligence Virtual Event on December 15, 2022 gives overview of Ginkgo's approach to machine learning-guided enzyme engineering Enzymes are valuable biocatalysts used across a wide range of ...

Ginkgo Bioworks (NYSE: DNA) stock has had a rough 12 months, falling 88%, and undergoing a reverse stock split on Aug. 20 that left its shares down by around 18% in the aftermath. Depending on which ...

At its 15th anniversary event in Ede on October 15, Wageningen-based agrifood accelerator StartLife made two major ...

BERLIN and BOSTON, April 18, 2023 /PRNewswire/ -- Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, ...

Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right now ...

Ginkgo Bioworks' Q3 results were relatively poor due to the difficult macro environment and the winding down of its COVID testing business. While Ginkgo's Cell Engineering business has enormous ...

Ginkgo Bioworks went public two years ago via a special purpose acquisition company. Deep losses and significant cash burn have made investors wary of investing in this risky stock. Special purpose ...